Computational microbiome pharmacology analysis elucidates the anti-cancer potential of vaginal microbes and metabolites.

ABSTRACT: The vaginal microbiome's role in risk, progression, and treatment of female cancers has been widely explored. Yet, there remains a need to develop methods to understand the interaction of microbiome factors with host cells and to characterize their potential therapeutic functions. To address this challenge, we developed a systems biology framework we term the Pharmacobiome for microbiome pharmacology analysis. The Pharmacobiome framework evaluates similarities between microbes, microbial byproducts, and known drugs based on their impact on host transcriptomic cellular signatures. Here, we apply our framework to characterization of the Anti-Gynecologic Cancer Vaginal Pharmacobiome. Using published vaginal microbiome multi-omics data from the Partners PrEP clinical trial, we constructed vagi

SUBMITTER: Lawore DC 

PROVIDER: S-EPMC12479523 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature